Varnimcabtagene autoleucel

法基奥仑赛

Report date: 2023/03/17 14:22:04

Base Information

Drug NameVarnimcabtagene autoleucel
Drug Alias NameARI-0001IMN-003AIMN-003-A
ClassificationCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Lentiviral vectorCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapyCell and gene therapy > Cell therapy > Donor > Autologous +[4] 
Mechanisms of ActionT lymphocyte replacementsImmunologic cytotoxicityB-lymphocyte antigen CD19 modulators
TargetsB-lymphocyte antigen CD19
Therapy Area/IndicationsLymphoma, Large B-Cell, DiffuseLymphoma, Non-HodgkinPrecursor Cell Lymphoblastic Leukemia-Lymphoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryNetherlandsSpain
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesHospital Clínic De BarcelonaInstitut D'Investigacions Biomèdiques August Pi I Sunyer
China Registration ClassN/A

Develop Information

Active CompaniesUniversity Medical Center GroningenInstitut D'Investigacions Biomèdiques August Pi I Sunyer
Inactive CompaniesN/A
Active IndicationsLymphoma, Large B-Cell, DiffuseLymphoma, Non-HodgkinPrecursor Cell Lymphoblastic Leukemia-Lymphoma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A